vs

Side-by-side financial comparison of AEHR TEST SYSTEMS (AEHR) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

AEHR TEST SYSTEMS is the larger business by last-quarter revenue ($9.9M vs $5.5M, roughly 1.8× Taysha Gene Therapies, Inc.). AEHR TEST SYSTEMS runs the higher net margin — -32.7% vs -507.8%, a 475.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -26.5%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 14.3%).

Aehr Test Systems designs, manufactures and sells advanced test and burn-in systems for the global semiconductor industry. Its products help semiconductor manufacturers, packaging firms and chip designers validate reliability of logic, memory and power semiconductor devices, serving markets across North America, Asia and Europe.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

AEHR vs TSHA — Head-to-Head

Bigger by revenue
AEHR
AEHR
1.8× larger
AEHR
$9.9M
$5.5M
TSHA
Growing faster (revenue YoY)
TSHA
TSHA
+197.8% gap
TSHA
171.3%
-26.5%
AEHR
Higher net margin
AEHR
AEHR
475.1% more per $
AEHR
-32.7%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
14.3%
AEHR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AEHR
AEHR
TSHA
TSHA
Revenue
$9.9M
$5.5M
Net Profit
$-3.2M
$-27.9M
Gross Margin
25.7%
Operating Margin
-47.0%
-516.0%
Net Margin
-32.7%
-507.8%
Revenue YoY
-26.5%
171.3%
Net Profit YoY
-214.2%
-48.3%
EPS (diluted)
$-0.11
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AEHR
AEHR
TSHA
TSHA
Q4 25
$9.9M
$5.5M
Q3 25
$11.0M
$0
Q2 25
$14.1M
$2.0M
Q1 25
$18.3M
$2.3M
Q4 24
$13.5M
$2.0M
Q3 24
$13.1M
$1.8M
Q2 24
$16.6M
$1.1M
Q1 24
$7.6M
$3.4M
Net Profit
AEHR
AEHR
TSHA
TSHA
Q4 25
$-3.2M
$-27.9M
Q3 25
$-2.1M
$-32.7M
Q2 25
$-2.9M
$-26.9M
Q1 25
$-643.0K
$-21.5M
Q4 24
$-1.0M
$-18.8M
Q3 24
$660.0K
$-25.5M
Q2 24
$23.9M
$-20.9M
Q1 24
$-1.5M
$-24.1M
Gross Margin
AEHR
AEHR
TSHA
TSHA
Q4 25
25.7%
Q3 25
33.9%
Q2 25
30.3%
Q1 25
39.2%
Q4 24
40.1%
Q3 24
54.0%
Q2 24
50.9%
Q1 24
41.7%
Operating Margin
AEHR
AEHR
TSHA
TSHA
Q4 25
-47.0%
-516.0%
Q3 25
-37.1%
Q2 25
-22.7%
-1347.1%
Q1 25
-6.1%
-930.5%
Q4 24
-11.2%
-985.8%
Q3 24
1.2%
-1448.4%
Q2 24
15.3%
-1915.4%
Q1 24
-27.1%
-713.3%
Net Margin
AEHR
AEHR
TSHA
TSHA
Q4 25
-32.7%
-507.8%
Q3 25
-19.0%
Q2 25
-20.6%
-1353.6%
Q1 25
-3.5%
-935.2%
Q4 24
-7.6%
-929.0%
Q3 24
5.0%
-1427.5%
Q2 24
143.8%
-1882.0%
Q1 24
-19.4%
-705.4%
EPS (diluted)
AEHR
AEHR
TSHA
TSHA
Q4 25
$-0.11
$-0.08
Q3 25
$-0.07
$-0.09
Q2 25
$-0.10
$-0.09
Q1 25
$-0.02
$-0.08
Q4 24
$-0.03
$-0.07
Q3 24
$0.02
$-0.10
Q2 24
$0.81
$-0.09
Q1 24
$-0.05
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AEHR
AEHR
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$30.8M
$319.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$130.8M
$246.9M
Total Assets
$148.7M
$343.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AEHR
AEHR
TSHA
TSHA
Q4 25
$30.8M
$319.8M
Q3 25
$22.7M
$297.3M
Q2 25
$24.5M
$312.8M
Q1 25
$29.4M
$116.6M
Q4 24
$32.2M
$139.0M
Q3 24
$37.8M
$157.7M
Q2 24
$49.2M
$172.7M
Q1 24
$47.6M
$124.0M
Stockholders' Equity
AEHR
AEHR
TSHA
TSHA
Q4 25
$130.8M
$246.9M
Q3 25
$122.4M
$219.0M
Q2 25
$122.9M
$248.7M
Q1 25
$124.2M
$55.1M
Q4 24
$123.2M
$71.5M
Q3 24
$122.5M
$88.8M
Q2 24
$111.6M
$108.9M
Q1 24
$86.5M
$53.8M
Total Assets
AEHR
AEHR
TSHA
TSHA
Q4 25
$148.7M
$343.3M
Q3 25
$144.1M
$316.6M
Q2 25
$148.5M
$333.3M
Q1 25
$145.6M
$138.4M
Q4 24
$142.3M
$160.4M
Q3 24
$145.9M
$180.2M
Q2 24
$127.9M
$200.4M
Q1 24
$101.6M
$153.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AEHR
AEHR
TSHA
TSHA
Operating Cash FlowLast quarter
$-1.2M
$-26.7M
Free Cash FlowOCF − Capex
$-1.6M
FCF MarginFCF / Revenue
-16.6%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AEHR
AEHR
TSHA
TSHA
Q4 25
$-1.2M
$-26.7M
Q3 25
$-282.0K
$-24.2M
Q2 25
$-2.3M
$-20.2M
Q1 25
$-1.6M
$-22.0M
Q4 24
$-5.9M
$-18.3M
Q3 24
$2.4M
$-21.6M
Q2 24
$1.2M
$-21.5M
Q1 24
$-2.8M
$-19.8M
Free Cash Flow
AEHR
AEHR
TSHA
TSHA
Q4 25
$-1.6M
Q3 25
$-1.7M
$-24.3M
Q2 25
$-5.1M
Q1 25
$-3.3M
Q4 24
$-6.2M
$-18.3M
Q3 24
$2.2M
$-21.6M
Q2 24
$1.2M
$-21.7M
Q1 24
$-3.1M
$-19.9M
FCF Margin
AEHR
AEHR
TSHA
TSHA
Q4 25
-16.6%
Q3 25
-15.3%
Q2 25
-36.3%
Q1 25
-17.8%
Q4 24
-46.0%
-905.5%
Q3 24
16.6%
-1210.9%
Q2 24
7.1%
-1951.9%
Q1 24
-40.8%
-584.5%
Capex Intensity
AEHR
AEHR
TSHA
TSHA
Q4 25
4.7%
Q3 25
12.7%
Q2 25
20.0%
Q1 25
9.0%
Q4 24
2.4%
0.1%
Q3 24
1.5%
2.0%
Q2 24
0.3%
18.1%
Q1 24
3.5%
4.1%
Cash Conversion
AEHR
AEHR
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.61×
Q2 24
0.05×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AEHR
AEHR

Systems$5.0M50%
Contactors$3.4M35%
Services$1.5M15%

TSHA
TSHA

Segment breakdown not available.

Related Comparisons